Navigation Links
Video: CVS/pharmacy and National Council on Aging Help Seniors to Find the Right 'Prescription' for Medicare Savings
Date:11/12/2008

care Part D beneficiaries would have saved over $250 a year on total drug costs if they had chosen a plan that better fit their situation.

"We urge people who qualify for the prescription drug benefit to consider their options and realize the potential to save," said Stuart Spector, Senior Vice President, NCOA. "Prescription drug coverage can make a significant difference in the health and lives of people with Medicare, especially those with limited income and resources who may qualify for the extra help."

The six-week Medicare Part D enrollment period lasts from Nov. 15 through Dec. 31. When evaluating plans, CVS/pharmacy and NCOA recommend three factors for consideration:

-- Cost: What is the plan deductible, monthly premium and prescription

co-pay for the prescriptions you regularly take?

-- Coverage: Are the prescription medications you regularly take covered in

the plan? Are there restrictions such as prior authorization?

-- Convenience: Can you fill the prescription at the pharmacy of your

choice?

The CVS/pharmacy Medicare Part D Calculator guides seniors through this decision-making process step by step. After entering basic information such as ZIP code, current prescription drug coverage, and prescription medications, seniors are guided through a series of options:

-- Seniors can indicate whether they prefer to find plans with the lowest

annual cost or find plans that cover all current medications with the

fewest coverage limitations even if it means paying higher annual costs

-- They can also make choices about medication in the coverage gap -- also

known as the "donut hole"

-- Seniors can find out if they qualify for Extra Help from the Social

Security Administration

Lastly, seniors are presented with a list of the top plans that best meet their needs, including information on estimated annual cost, month
'/>"/>

SOURCE CVS/pharmacy
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Video: Nation Gets a D as March Of Dimes Releases Premature Birth Report Card
2. Video: MassMutual Enhances Whole Life Insurance Products - Provides Flexibility, Guarantees
3. Video: Ultrasound Systems Can Produce Clearer Images With TIs New Family of Fully Integrated High-Voltage Pulsers and Switches
4. Video: Medical Imaging Equipment OEMs Can Achieve Faster, More Accurate Results with TIs Portfolio of Embedded Processors and Analog Products
5. Video: BrainLine.org Confronts Traumatic Brain Injury Crisis
6. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Video: Diabetes Ten City Challenge Celebrates Three Years of Success:
8. Video: Regular Vacations: Prescription for a Healthy Lifestyle
9. Video: The Cigarette Is Dead Social Movement Takes Aim at Deadly Icon
10. Video: Never Feel Bad About Your Neck Again:
11. Video: The Science Behind the Soak - a Coping Tool for Todays Changing World
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 1Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 2Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 4Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 5Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 6Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 7Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 8Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 1Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 2